Arcutis Biotherapeutics, Inc. (ARQT) Reports Q4 Loss, Tops Revenue Estimates

Group 1 - Arcutis Biotherapeutics reported a quarterly loss of $0.09 per share, significantly better than the Zacks Consensus Estimate of a loss of$ 0.27, and an improvement from a loss of $0.72 per share a year ago, resulting in an earnings surprise of 66.67% [1] - The company achieved revenues of$ 71.36 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 23.56%, and showing a substantial increase from $13.53 million in the same quarter last year [2] - Over the last four quarters, Arcutis has surpassed consensus EPS estimates four times and topped revenue estimates twice [2] Group 2 - The stock has underperformed the market, losing about 11.1% since the beginning of the year, while the S&P 500 has gained 1.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$ 0.26 on revenues of $61 million, and for the current fiscal year, it is -$ 0.90 on revenues of $277.07 million [7] Group 3 - The Zacks Industry Rank places the Medical - Biomedical and Genetics sector in the top 27% of over 250 Zacks industries, indicating a favorable outlook for stocks in this sector [8] - The estimate revisions trend for Arcutis Biotherapeutics is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6]